CL2015000426A1 - Uso del profarmaco ester de etilo del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-4-amino-(2r)-metilbutanoico o del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-(2r)-4-amino-metilbutanoico, inhibidores de nep, junto a valsartan, para tratar la insuficiencia cardiaca con fraccion de eyeccion preservada. - Google Patents

Uso del profarmaco ester de etilo del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-4-amino-(2r)-metilbutanoico o del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-(2r)-4-amino-metilbutanoico, inhibidores de nep, junto a valsartan, para tratar la insuficiencia cardiaca con fraccion de eyeccion preservada.

Info

Publication number
CL2015000426A1
CL2015000426A1 CL2015000426A CL2015000426A CL2015000426A1 CL 2015000426 A1 CL2015000426 A1 CL 2015000426A1 CL 2015000426 A CL2015000426 A CL 2015000426A CL 2015000426 A CL2015000426 A CL 2015000426A CL 2015000426 A1 CL2015000426 A1 CL 2015000426A1
Authority
CL
Chile
Prior art keywords
phenylphenylmethyl
carboxy
amino
oxopropyl
methylbutanoic
Prior art date
Application number
CL2015000426A
Other languages
English (en)
Inventor
Christoph Shumacher
Thomas Holbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49000959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000426(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2015000426A1 publication Critical patent/CL2015000426A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2015000426A 2012-08-24 2015-02-23 Uso del profarmaco ester de etilo del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-4-amino-(2r)-metilbutanoico o del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-(2r)-4-amino-metilbutanoico, inhibidores de nep, junto a valsartan, para tratar la insuficiencia cardiaca con fraccion de eyeccion preservada. CL2015000426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261692911P 2012-08-24 2012-08-24

Publications (1)

Publication Number Publication Date
CL2015000426A1 true CL2015000426A1 (es) 2015-10-02

Family

ID=49000959

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000426A CL2015000426A1 (es) 2012-08-24 2015-02-23 Uso del profarmaco ester de etilo del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-4-amino-(2r)-metilbutanoico o del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-(2r)-4-amino-metilbutanoico, inhibidores de nep, junto a valsartan, para tratar la insuficiencia cardiaca con fraccion de eyeccion preservada.

Country Status (27)

Country Link
US (3) US9517226B2 (es)
EP (2) EP3943084A1 (es)
JP (4) JP6482462B2 (es)
KR (2) KR20200111822A (es)
CN (2) CN108685889A (es)
AU (1) AU2013304949C1 (es)
BR (1) BR112015003067A2 (es)
CA (1) CA2882771C (es)
CL (1) CL2015000426A1 (es)
DK (1) DK2887961T3 (es)
ES (1) ES2879550T3 (es)
HK (1) HK1205930A1 (es)
HU (1) HUE054885T2 (es)
IL (1) IL237114B (es)
MA (1) MA37850A1 (es)
MX (1) MX2015002432A (es)
NZ (1) NZ704604A (es)
PH (1) PH12015500375A1 (es)
PL (1) PL2887961T3 (es)
PT (1) PT2887961T (es)
RU (1) RU2667643C2 (es)
SG (1) SG11201500256UA (es)
SI (1) SI2887961T1 (es)
TN (1) TN2015000028A1 (es)
TW (1) TWI634887B (es)
WO (1) WO2014029848A1 (es)
ZA (1) ZA201500262B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MA37850A1 (fr) 2012-08-24 2018-07-31 Novartis Ag Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
WO2015028941A1 (en) * 2013-08-26 2015-03-05 Novartis Ag New use
US9526728B2 (en) * 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
US20180140579A1 (en) 2015-05-29 2018-05-24 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
JP6598985B2 (ja) 2015-08-28 2019-10-30 ノバルティス アーゲー 新規の使用
US20190054069A1 (en) 2016-02-03 2019-02-21 Novartis Ag New use of a combination of sacubitril and valsartan
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
UY38072A (es) * 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2020185479A1 (en) 2019-03-08 2020-09-17 Boehringer Ingelheim International Gmbh Anti-il-36r antibody formulations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3004206A1 (de) 1980-02-06 1981-08-13 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von 1-alkyl-1-phenylhydrazinen
DE3005674A1 (de) 1980-02-15 1981-08-20 Ruhr-Zink GmbH, 4354 Datteln Verwendung einer blei-legierung fuer anoden bei der elektrolytischen gewinnung von zink
DE3010374A1 (de) 1980-03-18 1981-10-08 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von copolymerisaten von styrol und/oder dessen derivaten
US4610816A (en) 1980-12-18 1986-09-09 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4383527A (en) 1981-02-20 1983-05-17 Howmedica, Inc. Device for guiding the insertion of surgical wires into bone tissue
DE3173350D1 (en) 1981-04-24 1986-02-13 Jean Martin Prefabricated unit for the realization of a construction frame
ZA84670B (en) 1983-01-31 1985-09-25 Merck & Co Inc Thiorphan analogs as enkephalinase and angiotensin converting enzyme inhibitors
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4929641B1 (en) 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
US4740499A (en) 1986-07-28 1988-04-26 Monsanto Company Method of enhancing the bioactivity of atrial peptides
GB8811873D0 (en) 1988-05-19 1988-06-22 Pfizer Ltd Therapeutic agents
GB8812597D0 (en) 1988-05-27 1988-06-29 Pfizer Ltd Therapeutic agents
GB2218983A (en) 1988-05-27 1989-11-29 Pfizer Ltd Spiro-substituted glutaramides as diuretics
EP0361365A1 (en) 1988-09-30 1990-04-04 E.R. SQUIBB & SONS, INC. Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use
GB8903740D0 (en) 1989-02-18 1989-04-05 Pfizer Ltd Therapeutic agents
DK0443983T3 (da) 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5294632A (en) 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
US5250522A (en) 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
GB9123353D0 (en) 1991-11-04 1991-12-18 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1993010773A1 (en) 1991-12-06 1993-06-10 Schering-Plough S.P.A. Use of neutral endopeptidase inhibitors in the treatment of left ventricular hypertrophy
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
DE4233296C1 (de) 1992-10-02 1994-03-31 Heitland Und Petre Int Gmbh Behälter für Kosmetikprodukte
WO1994015908A1 (en) 1993-01-14 1994-07-21 Yoshitomi Pharmaceutical Industries, Ltd. Propionamide derivative and medicinal use thereof
JPH06234754A (ja) 1993-02-10 1994-08-23 Dai Ichi Seiyaku Co Ltd 複素環式カルボン酸誘導体
IT1266571B1 (it) 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
JP3576193B2 (ja) 1993-12-03 2004-10-13 第一製薬株式会社 ビフェニルメチル置換バレリルアミド誘導体
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
CN1615134A (zh) 2002-01-17 2005-05-11 诺瓦提斯公司 含有缬沙坦和nep抑制剂的药物组合物
RU2245162C2 (ru) * 2003-01-04 2005-01-27 Козлов Владимир Александрович Способ терапии инфаркта миокарда
MXPA05012299A (es) 2003-05-16 2006-01-30 Novartis Ag Composicion farmaceutica que comprende valsartan.
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
ES2536514T3 (es) * 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
CA2807830C (en) * 2010-08-24 2018-04-03 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
MA37850A1 (fr) 2012-08-24 2018-07-31 Novartis Ag Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale

Also Published As

Publication number Publication date
RU2018126749A (ru) 2019-03-12
AU2013304949A1 (en) 2015-02-05
JP2015526458A (ja) 2015-09-10
CN108685889A (zh) 2018-10-23
HUE054885T2 (hu) 2021-10-28
TN2015000028A1 (en) 2016-06-29
ZA201500262B (en) 2016-09-28
SI2887961T1 (sl) 2021-08-31
TW201414471A (zh) 2014-04-16
JP2022020624A (ja) 2022-02-01
CA2882771C (en) 2021-02-23
PH12015500375A1 (en) 2015-04-20
MA37850A1 (fr) 2018-07-31
RU2018126749A3 (es) 2021-12-28
RU2667643C2 (ru) 2018-09-21
JP2023159114A (ja) 2023-10-31
IL237114A0 (en) 2015-03-31
EP3943084A1 (en) 2022-01-26
ES2879550T3 (es) 2021-11-22
US11135192B2 (en) 2021-10-05
JP6482462B2 (ja) 2019-03-13
US9517226B2 (en) 2016-12-13
PL2887961T3 (pl) 2021-11-08
CA2882771A1 (en) 2014-02-27
IL237114B (en) 2020-10-29
DK2887961T3 (da) 2021-07-19
EP2887961A1 (en) 2015-07-01
BR112015003067A2 (pt) 2017-07-04
HK1205930A1 (en) 2015-12-31
NZ704604A (en) 2018-06-29
WO2014029848A1 (en) 2014-02-27
US20180200218A1 (en) 2018-07-19
KR102159601B1 (ko) 2020-09-28
US20150190376A1 (en) 2015-07-09
MX2015002432A (es) 2015-06-22
US20170049738A1 (en) 2017-02-23
CN104602711A (zh) 2015-05-06
TWI634887B (zh) 2018-09-11
US9937143B2 (en) 2018-04-10
EP2887961B1 (en) 2021-04-28
JP7407508B2 (ja) 2024-01-04
JP2019069954A (ja) 2019-05-09
KR20200111822A (ko) 2020-09-29
PT2887961T (pt) 2021-07-28
SG11201500256UA (en) 2015-04-29
KR20150046039A (ko) 2015-04-29
AU2013304949B2 (en) 2016-08-11
AU2013304949C1 (en) 2020-12-24
RU2015110240A (ru) 2016-10-20

Similar Documents

Publication Publication Date Title
CL2015000426A1 (es) Uso del profarmaco ester de etilo del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-4-amino-(2r)-metilbutanoico o del acido n-(3-carboxi-1-oxopropil)-(4s)-p-fenilfenilmetil)-(2r)-4-amino-metilbutanoico, inhibidores de nep, junto a valsartan, para tratar la insuficiencia cardiaca con fraccion de eyeccion preservada.
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
MA41031A (fr) Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
DK3584255T3 (da) Modificerede aminosyrer omfattende en azidogruppe
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
CL2014000459A1 (es) Compuestos derivados de heterociclos biciclicos con nitrogeno; composicion farmaceutica; uso para tratar la hipertension arterial pulmonar.
IT1400982B1 (it) Collirio osmotico trans-epiteliale per la cura del cheratocono.
BR112014005914A2 (pt) Produto para cicatrização de feridas tecidulares
CL2013003129A1 (es) Composicion herbicida de emulsión de aceite en agua, estable de alta resistencia; metodo para preparar dicha composicion.
CL2013000801A1 (es) Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
BR112013020362A2 (pt) processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
BR112013031210A2 (pt) processo para o tratamento das fibras queratínicas, kit e uso de um dispositivo
EA201600495A1 (ru) Пролекарство адреномедуллина на основе полиэтиленгликоля и его применение
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
CL2014000490A1 (es) Compuestos derivados de pirazol y sus sales, con actividad inhibidora de sglt1; composicion farmaceutica que los comprende; y su uso para tratar o prevenir diabetes.
CL2013003563A1 (es) Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma.
BR112014026149A2 (pt) método para a preparação de 2,4-ácido dihidroxibutírico (2,4-dhb) e microrganismo.
CL2013000513A1 (es) Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.
BR112013022523A2 (pt) uso de glicopirrolato para o tratamento de taquicardia
CL2013001579A1 (es) Uso de una composicion farmaceutica que comprende un compuesto agonista ep4 para tratar marcas de la piel tales como heridas superficiales, cicatrices o arrugas.
BR112015010525A2 (pt) processo para alisamento de fibras de queratina, uso de uma composição e composição cosmética.
BR112014026795A2 (pt) composição cosmética , processo cosmético para tratar a matéria queratínica e uso de uma composição cosmética.
CL2013000831A1 (es) Metodo para la determinacion del contenido de alergenos de una composicion.
DK2667856T3 (da) Medicinsk indretning indeholdende en tørstofsammensætning omfattende aripiprazol som en aktiv ingrediens, og en tørstofsammensætning omfattende aripiprazol som en aktiv ingrediens